SCHEDULE: RA Capital Boosts Stake in Perceptive Capital, Backs Freenome Merger

RA Capital Management and its affiliates have increased their stake in Perceptive Capital Solutions Corp and are supporting its merger with Freenome Holdings, Inc., including a significant PIPE financing.

Summary

• RA Capital Management, L.P., Peter Kolchinsky, Rajeev Shah, and RA Capital Healthcare Fund, L.P. (Reporting Persons) beneficially own 750,000 Class A Ordinary Shares of Perceptive Capital Solutions Corp (PCSC), representing 8.4% of the class.
• The RA Capital Healthcare Fund, L.P. initially purchased these shares on June 13, 2024, for $7.5 million during PCSC's initial public offering (IPO).
• PCSC has entered into a Business Combination Agreement with Freenome Holdings, Inc. on December 5, 2025, which will result in PCSC domesticating as a Delaware corporation and changing its name to "Freenome, Inc." (New Freenome).
• The business combination implies a Freenome base equity value of $725,000,000.
• Concurrently, PCSC secured a PIPE (Private Investment in Public Equity) financing of $240,000,000 through the sale of 24,000,000 shares of New Freenome Common Stock at $10.00 per share to various investors.
• Investment funds advised by RA Capital, including the Fund, subscribed to purchase 5,255,376 shares in the PIPE financing for an aggregate of $54,553,760.
• Post-closing, investment funds advised by RA Capital are expected to own approximately 13% of the outstanding New Freenome Common Stock.
• Dr. Peter Kolchinsky, a current director of Freenome and a controlling person of RA Capital, is expected to join the New Freenome board of directors.
• Freenome Supporting Stockholders, including RA Capital advised funds, have entered into Transaction Support Agreements to vote in favor of the Business Combination.
• Certain stockholders, including RA Capital advised funds, will be subject to a six-month lock-up period post-closing, restricting share transfers.

Sentiment

Score: 8

Explanation: The filing details a significant strategic transaction (SPAC merger) for Perceptive Capital Solutions Corp with Freenome, backed by a substantial PIPE financing. The involvement of a major healthcare investor like RA Capital, increasing its stake and gaining board representation, signals strong confidence in the future combined entity. While there are standard closing conditions and a lock-up period, the overall tone is highly positive regarding the company's strategic direction and financial backing.

Positives

• Significant investment by RA Capital, a specialized healthcare investor, in both PCSC and the PIPE financing, indicating confidence in the combined entity, Freenome.
• The business combination with Freenome, a company in which RA Capital already holds an investment, suggests a strategic alignment and potential for growth in the healthcare sector.
• The PIPE financing of $240,000,000 provides substantial capital for the combined entity, Freenome, to support its operations and strategic initiatives.
• Dr. Peter Kolchinsky, a controlling person of RA Capital, joining the New Freenome board of directors brings experienced leadership and oversight.

Negatives

• The lock-up agreement restricts the transfer of shares for six months after the closing date for certain stockholders, including RA Capital advised funds, limiting liquidity during that period.
• The conversion of Freenome shares, options, and RSUs into New Freenome Common Stock and equity awards involves an exchange ratio and adjustments, which could introduce complexity and potential for value changes.

Risks

• The closing of the Business Combination is subject to requisite approvals from PCSC shareholders and Freenome stockholders, as well as other customary closing conditions, meaning the transaction is not guaranteed.
• The PIPE Financing is conditioned upon the satisfaction of all conditions precedent to the Closing of the Business Combination, posing a risk if the merger does not complete.
• The Reporting Persons may acquire additional securities or dispose of existing ones, which could impact the market price and ownership structure.

Future Outlook

The combined entity, New Freenome, is expected to benefit from a significant capital injection from the PIPE financing and strategic guidance from its new board, including Dr. Peter Kolchinsky. The company plans to file a registration statement for the resale of certain shares post-closing, and key stockholders will be subject to a six-month lock-up period.

Management Comments

• The Reporting Persons initially acquired the Class A ordinary shares reported herein for investment purposes and not with an intent, purpose or effect of changing control of the Issuer, and such acquisitions were made in the Reporting Persons' ordinary course of business.
• The Reporting Persons may, from time to time, acquire additional equity securities or debt securities of the Issuer... or dispose of Issuer securities they beneficially own... consistent with their investment purposes.
• Dr. Kolchinsky will engage in regular discussions with the board of directors and management as part of his duties as a director.

Industry Context

This transaction represents a SPAC merger in the healthcare/biotechnology sector, a common strategy for private companies like Freenome to go public and raise significant capital. The involvement of a specialized healthcare investor like RA Capital Management, which was already a Freenome stockholder, suggests a strong belief in Freenome's technology and market potential within the diagnostics or therapeutics space. The substantial PIPE financing indicates continued investor appetite for promising companies in this sector, even amidst broader market volatility.

Comparison to Industry Standards

• The implied Freenome base equity value of $725 million positions it as a significant player in the diagnostics/biotechnology space, comparable to other emerging companies in the field.
• The $240 million PIPE financing is a substantial capital raise for a SPAC transaction, indicating strong institutional investor confidence, similar to successful biotech SPACs that have attracted significant funding rounds.
• The 6-month lock-up period for key stockholders is a standard practice in SPAC mergers, aligning with industry norms to ensure stability post-merger.

Management Changes

Corporate Governance

Related Party Transactions

• Investment funds advised by RA Capital, including the Fund, are current stockholders of Freenome.
• Investment funds advised by RA Capital, including the Fund, subscribed to purchase 5,255,376 shares in the PIPE Financing for $54,553,760.
• Investment funds advised by RA Capital are Freenome Supporting Stockholders and entered into Transaction Support Agreements.
• Investment funds advised by RA Capital will be parties to the Investor Rights Agreement and the Lock-Up Agreement.
• Dr. Peter Kolchinsky, a controlling person of RA Capital, is a current director of Freenome and is expected to join the New Freenome board.

Stakeholder Impact

• Shareholders (PCSC): Their Class A Ordinary Shares will be converted into New Freenome Common Stock, and they will become shareholders of the combined, publicly traded Freenome, Inc. The merger and PIPE financing could enhance the value of their holdings.
• Stockholders (Freenome): Their Freenome common stock, options, and RSUs will be converted into New Freenome Common Stock and equity awards, providing liquidity and public market access.
• PIPE Investors: Will acquire New Freenome Common Stock at a set price, providing capital to the combined entity and becoming significant shareholders.
• Employees (Freenome): Their equity awards will convert to New Freenome equity awards, maintaining their incentives within the new public company structure.
• Management (Freenome/PCSC): Will lead the combined entity, Freenome, Inc., with a strengthened balance sheet and public market presence.
• RA Capital Management: Increases its strategic investment and influence in Freenome, with Dr. Kolchinsky joining the board, potentially enhancing returns for their fund investors.

Next Steps

• PCSC will de-register from the Cayman Islands and domesticate as a Delaware corporation, changing its name to "Freenome, Inc.".
• The Business Combination will proceed with Merger Sub I merging into Freenome, followed by Freenome merging into Merger Sub II.
• PCSC shareholders and Freenome stockholders must approve the Business Combination.
• The PIPE Financing will close upon satisfaction of all conditions precedent to the Business Combination.
• New Freenome will file a registration statement for the resale of certain shares within 30 calendar days following the Closing Date.
• Dr. Kolchinsky is expected to join the New Freenome board of directors.

Key Dates

Recommendation

The filing details a definitive business combination agreement between Perceptive Capital Solutions Corp and Freenome Holdings, Inc., a significant event for both entities. The substantial PIPE financing of $240 million, with strong participation from a reputable healthcare investor like RA Capital Management (who is also increasing its overall stake and gaining board representation), provides robust capital for the combined entity. This strategic merger, coupled with significant institutional backing, positions the future 'Freenome, Inc.' for strong growth and market penetration in the healthcare sector. The implied Freenome base equity value of $725 million suggests a solid foundation. While customary closing conditions exist, the comprehensive agreements and investor commitments indicate a high probability of successful completion, making this an attractive long-term investment opportunity.

Keywords

Perceptive Capital Solutions Corp, Freenome Holdings Inc, RA Capital Management, Business Combination Agreement, PIPE Financing, SPAC Merger, Healthcare Investment, Class A Ordinary Shares, Schedule 13D, Biotechnology, Diagnostics